Strategic expansion Circulogene is actively broadening its diagnostic capabilities with tissue-based OncoGenDx and LungLifeAI offerings, signaling opportunities to upsell integrated liquid and tissue assay bundles to oncology clinics, hospital labs, and primary care networks seeking comprehensive cancer genomics and AI-driven IPN assessment.

AI driven diagnostics The LungLifeAI launch and indeterminate pulmonary nodule focus indicate strong demand for AI-enhanced, blood-based decision support. Target hematology-oncology practices, pulmonology centers, and imaging networks with value propositions around faster risk stratification and non-invasive monitoring.

PD-L1 and immunotherapy Circulogene highlights PD-L1 biomarker testing via a simple blood test, enabling immunotherapy prediction. Promote opportunities with oncology groups, pharma collaborators, and CROs seeking non-invasive, scalable PD-L1 profiling for patient selection and trial enrichment.

Growth in Pensacola Recent expansion into Pensacola, Florida, suggests a regional sales focus and channel development potential in the Southeast. Leverage local partnerships, independent clinics, and academic centers to establish a foothold for expanded service offerings and reference sites.

Financial and scale signals With mid-market revenue in the tens of millions and a growth-oriented product slate, Circulogene appears positioned for channel partnerships, OEM collaborations, and contract research arrangements with mid-sized labs and specialty clinics seeking scalable NGS and liquid biopsy workflows.